January. 13, 2023
QureBio Q-1801 Project was approved by CDE

December. 21, 2022
QureBio Ltd. to Present its Q-1802 Clinical Phase Ⅰ Data at 2023 ASCO-GI Meetings

September. 19, 2022
QureBio Q-1801 project was approved by FDA

October. 25, 2022
QureBio Q-1801 clinical trial application was accepted by NMPA

May. 31, 2022
QureBio Ltd. to Showcase its Q-1802 Clinical Advances at 2022 ASCO Annual Meetings

April. 12, 2022
QureBio's First Bispecific Antibody Q-1802 Combination Clinical Trial (phase I/II) Was Approved

March. 08, 2022
Leaders of Zhangjiang Biotech&Pharmaceutical Base visited Qure Bio for investigation and research

December. 23, 2021
Qure Bio completed nearly 200 million yuan in Series B financing

September. 17, 2021
Qure Bio's Q-1802 combined with Hengrui Pharma's Apatinib in clinical research

August. 30, 2021
Qure Bio and BioMap announced a strategic cooperation: the combination of IT and BT to discover new targets and new drugs

August. 25, 2021
Qure Bio will develop new types of immune cell therapy for solid tumors in partnership with BRL Medicine

June. 18, 2021
The enrollment of the first patient in phase I clinical trials of the first Claudin18.2/PD-L1 bispecific antibody

February. 27, 2021
Qure Bio’s Bispecific Antibody Q-1802 Obtained IND Approval in the U.S

December. 24, 2020
Qure Bio Q-1802 clinical application was accepted by CDE

July. 31, 2020
Qure Bio obtained a pre-B round of financing of tens of millions of yuan

April. 10, 2020
Qure Bio completes tens of millions of yuan in A+ round of financing